[manmal]

They could market it as an exclusion test - "Congrats, you will not have Alzheimer's in the next 15 years" vs "Sorry, we can't say for sure that you don't have Alzheimer's. Why not upload your 23andme data here, and we combine your high risk alleles with our confidence of you having the disease, to produce a higher confidence result. Also, here is a list of lifestyle changes that reduce your risk of Alzheimer's (and also stroke, heart attack etc)".

[kvejdani]

We understand the level of rightful skepticism from the community given all previous failed big claims by others. There are many tests to tell you the risk of developing dementia, which is merely a "probability" number. Darmiyan's brain maps show (and measure) the actual pathology (neurodegeneration) in the brain, at microscopic resolution.

There is currently no other method to detect and quantify micro-structural abnormality in the brain at presymptomatic stages of dementia, which is one of the main reasons why all clinical trials of Alzheimer's test drugs keep failing one after another.

When a disease-modifying treatment is found using our technology (and practically impossible without it), the person who knows the status of their brain health will be the one to benefit most from the treatment before developing symptoms.

[x0x0]

Why do you think a lack of ability to detect/quantify these micro-structural abnormalities is hindering clinical trials? Is it a problem of detection lag?

How will your tech enable a disease-modifying treatment? Is the hypothesis your tech is the first way we can even measure?

Are you using standard MRIs and just a layer of software, or do you require some sort of special physical device?

This is all curiosity btw; I love the idea. I used to work on software for confocal microscopy and protein melting curves (to be clear, two different labs) before selling out and working on ads.